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DOI 10.1186/s40478-016-0307-6RESEARCH Open AccessTP53 hotspot mutations are predictive of
survival in primary central nervous system
lymphoma patients treated with
combination chemotherapy
Helga D. Munch-Petersen1,2, Fazila Asmar1, Konstantinos Dimopoulos1, Aušrinė Areškevičiūtė2, Peter Brown1,
Mia Seremet Girkov1, Anja Pedersen1, Lene D. Sjö2, Steffen Heegaard2,3, Helle Broholm2, Lasse S. Kristensen1,
Elisabeth Ralfkiaer2 and Kirsten Grønbæk1*Abstract
Primary central nervous system lymphoma (PCNSL) is an aggressive variant of diffuse large B-cell lymphoma (DLBCL)
confined to the CNS. TP53 mutations (MUT-TP53) were investigated in the context of MIR34A/B/C- and DAPK promoter
methylation status, and associated with clinical outcomes in PCNSL patients. In a total of 107 PCNSL patients clinical data
were recorded, histopathology reassessed, and genetic and epigenetic aberrations of the p53-miR34-DAPK network
studied. TP53 mutational status (exon 5–8), with structural classification of single nucleotide variations according to the
IARC-TP53-Database, methylation status of MIR34A/B/C and DAPK, and p53-protein expression were assessed. The 57/107
(53.2 %) patients that were treated with combination chemotherapy +/− rituximab (CCT-treated) had a significantly
better median overall survival (OS) (31.3 months) than patients treated with other regimens (high-dose methotrexate/
whole brain radiation therapy, 6.0 months, or no therapy, 0.83 months), P < 0.0001. TP53 mutations were identified in 32/
86 (37.2 %), among which 12 patients had hotspot/direct DNA contact mutations. CCT-treated patients with PCNSL
harboring a hotspot/direct DNA contact MUT-TP53 (n = 9) had a significantly worse OS and progression free survival (PFS)
compared to patients with non-hotspot/non-direct DNA contact MUT-TP53 or wild-type TP53 (median PFS 4.6 versus 18.2
or 45.7 months), P = 0.041 and P = 0.00076, respectively. Multivariate Cox regression analysis confirmed that hotspot/
direct DNA contact MUT-TP53 was predictive of poor outcome in CCT-treated PCNSL patients, P = 0.012 and P = 0.008;
HR: 1.86 and 1.95, for OS and PFS, respectively. MIR34A, MIR34B/C, and DAPK promoter methylation were detected in 53/
93 (57.0 %), 80/84 (95.2 %), and 70/75 (93.3 %) of the PCNSL patients with no influence on survival. Combined MUT-TP53
and MIR34A methylation was associated with poor PFS (median 6.4 versus 38.0 months), P = 0.0070. This study suggests
that disruption of the p53-pathway by MUT-TP53in hotspot/direct DNA contact codons is predictive of outcome in
CCT-treated PCNSL patients, and concomitant MUT-TP53 and MIR34A methylation are associated with poor PFS.
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Primary central nervous system lymphoma (PCNSL) of
the diffuse large B-cell lymphoma (DLBCL) subtype is
an aggressive variant of DLBCL confined to the CNS
[44]. Patients with extra CNS DLBCL display diverse
clinical courses, which may be explained by considerable
heterogeneity of the clinical, morphological and cytogen-
etic phenotypes [29, 37, 40, 52]. PCNSL or CNS DLBCL
has specific features that further distinguish this subtype
from DLBCL [11, 44]. Despite extensive research, the clin-
ical outcome of patients diagnosed with PCNSL is still dis-
mal, a fact that cannot only be explained by the specific
anatomical site or the difficulty of drug-delivery across the
blood-brain-barrier [14, 15, 21, 30, 32, 36, 39, 54]. The
pathogenic mechanisms driving this disease are still not
clear, and only few genetic or epigenetic aberrations have
been suggested as predictive or prognostic markers in
PCNSL [1, 29, 31].
The TP53 tumor suppressor gene plays important
roles in the regulation of cell proliferation, apoptosis and
genomic integrity. Under stressful conditions, i.e. DNA
damage, hypoxia, or oncogenic activation, the wild-type
TP53 (WT-TP53) gene product p53 mediates cell-cycle
arrest and preserves genomic stability via transcription-
dependent activity (TA) and transcription-independent ac-
tivity (TIA) in the cell. Reversely, the mutant p53 protein
may be non-functional or have gain-of-function properties
both leading to genomic instability and uncontrolled pro-
liferation of damaged cells [27, 33, 34, 43, 51].
In DLBCL outside the CNS, TP53 mutations (MUT-
TP53) have mostly been studied with emphasis on the
disruption of the coding sequences of the DNA binding
domain (DBD) (exons 5–8) with a reported mutation
frequency of ~20–25 % [35, 52]. Structural classification
and functional characteristics of MUT-TP53 assessed by
yeast-based functional assays, available in the Inter-
national Agency for Research on Cancer (IARC)-TP53-
Database (http://www.iarc.fr), have been reported in
DLBCL, with worse prognosis associated with mutations
in the DBD of TP53 [35, 51, 52]. Indeed, the majority of
cancer-related TP53 mutations occur in the region of
the DBD, which contains the Loop (L1)-sheet-helix
(LSH) motif, two large loops L2 and L3, the direct DNA
contact areas including the zinc-binding site, and the
hotspots [5, 9, 51, 52]. Few previous studies that report
TP53 mutation status in PCNSL reveal incidences <10 %
[10, 31], while, paradoxically, other investigations show
higher incidences of p53 protein expression by immun-
histochemistry (IHC) (29–60 %) as a surrogate marker
of MUT-TP53 [3, 6].
The members of the miR34-family (A/B/C) have been
recognized as tumor suppressors, which are implicated
in a variety of cellular processes that control carcinogen-
esis in concert with p53 [13, 19]. The miR34s have beenplaced at the center of the cell-cycle and apoptosis regu-
lation, and loss of miR34A has been associated with
poor response to therapy [4, 20, 25]. We recently investi-
gated the MIR34-family in a cohort of 150 primary
DLBCL patients, and identified promoter methylation,
and hence inactivation, of MIR34A in 28 % of the pa-
tients, and thereby showed that concomitant (”double
hit”) TP53 mutation and MIR34A methylation were re-
lated to an exceedingly poor median survival of only
9.4 months [4, 20]. We also investigated the methylation
status of DAPK (death-associated protein kinase), an-
other player in the p53 signaling network in DLBCL,
and showed that both overall- and allele specific DNA
methylation correlate with poor outcome. Here, patients
with concomitant TP53 mutation also had a tendency of
poorer survival [22].
Since these studies suggest that genetic- and epigenetic
disruption of the p53-miR34A-DAPK network may be
associated with worse outcome in DLBCL patients, we
speculated whether this pathway was also disrupted in
CNS DLBCL. Thus, the purpose of the current study
was to investigate and characterize the structural subsets
of TP53 mutations, and to evaluate these data in the
context of the MIR34 family- and DAPK promoter
methylation status to the clinical outcome in a large co-
hort of patients with PCNSL of the DLBCL subtype.
Methods and materials
Study population and patient samples
All patients, consecutively diagnosed with PCNSL of the
DLBCL subtype at our institution (University Hospital
of Copenhagen, Rigshospitalet) during a period of
13 years (2001–2014), were included. A total of 107
histological specimens, which were eligible for further
histopathological examination and DNA extraction for
molecular analyses, were reclassified by the authors
HDMP, HB, and ER (one training- and two specialist
neuro- and hematopathologists) according to the WHO-
classification [44]. In addition, data were extracted and
critically reviewed from the patient files, the national
Danish Pathology Database (Patobank), and the national
Danish Lymphoma Database (LYFO).
The clinical data included date of diagnosis, age, sex,
WHO performance status, serum lactate dehydrogenase
(LDH), International Prognostic Index (IPI), 1st line
treatment by chemo- and immunotherapy, whole brain
radiotherapy (WBRT) including number of fractions and
dose, adjuvant WBRT, response to treatment, relapse,
and death or last follow-up date.
Immunohistochemistry
Assessment of protein expression by immunohistochem-
istry (IHC) was done by re-evaluating a panel of anti-
bodies against: CD3, CD5, CD20, CD79A, CD10, BCL2,
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30 % was applied for all, except BCL2, where the cut-off
was set at 70 % [16]. p53 protein expression was
assessed by immunohistochemistry (IHC), see Additional
file 1: Methods 1, and evaluated semiquantitatively. On-
slide controls were used. No expression was defined as
0–9 %, and presence of expression was evaluated in in-
tervals of 10–25 %, 25–50 %, 50–75 %, 75–100 %. In the
survival analysis cut-off thresholds above 10 % were ap-
plied, as described by others [52, 53]. For the prolifera-
tion factor MIB-1 the percentage of stained nuclei was
evaluated.
DNA extraction from FFPE tissue
From all samples, DNA was isolated from 4 to 8 10 μm
FFPE (formalin-fixed paraffin-embedded) tissue sections
using the RecoverAllTM Total Nucleic Acid Isolation Kit
(Life Technologies, Carlsbad, CA, USA) according to the
manufacturers’ guidelines. Paraffin was removed from
the samples by Xylene incubation at 50 °C followed by
ethanol wash. Proteins were degraded by digestion buffer
and Proteinase-K digestion at 50°/80 °C. Subsequent iso-
lation of DNA was performed by addition of isolation
buffer and ethanol wash, followed by binding to a spin-
column system, and RNA degradation by RNAse treat-
ment. Total DNA was eluted in a 60 μL elution volume.
The quantity (260 nm) and quality (260/280 ratio) of
total DNA was measured by spectrophotometry on a
NanoDrop-1000 spectrophotometer (Thermo Scientific,
Delaware, USA).
Detection and structural classification of TP53 mutations
The coding sequences and splice sites of exons 5–8 of
the TP53 gene were screened for mutations by PCR and
denaturing gradient gel electrophoresis (DGGE) as de-
scribed previously [4, 17, 52]. By covering exon 5–8 it is
expected that ~95 % of TP53 mutations will be detected
[51, 52]. Positive samples were subjected to Sanger se-
quencing [51]. All mutations were confirmed twice from
DNA of the original sample.
Structural classification and nomenclature were ap-
plied using the IARC-TP53-Database (www.p53.iarc.fr)
version R17 [35]. The types of TP53 mutation (missense,
nonsense, deletion, insertion) and the sites of mutation
(exon, codon, functional domain, conserved area, CpG-
site relation, functional transactivation activity, and
SIFT-class) were determined. For tumors with more
than one mutation, the data for each mutation were re-
corded as separate entries in the absolute number of
mutations, but analyzed as single events for survival.
The most deleterious, i.e. functionally inactivating, mu-
tations were selected as representative for survival
analysis in these double mutated cases as in previously
published studies [52]. Single nucleotide variations(SNVs) were scanned in the IARC-TP53-Database for
detection of validated single nucleotide polymorphisms
(SNPs) [35, 47], and excluded. As described thoroughly
by Young et al. [52], we compared the survival of pa-
tients with MUT-TP53 within mutational subgroups or
with the survival of WT-TP53 patients. Structural sub-
sets, which were applied as factors in the survival ana-
lysis, included TP53 mutations located at hotspots in the
DBD including codons involved in direct DNA contact,
at the zinc-binding site, as well as frequent destabilizing
mutations in β-sheets. In the analysis, TP53 mutations lo-
cated in Loop-L2, Loop-L3, and LSH-motifs, conserved
areas 2–5, and CpG-sites were also incorporated, as well
as functional properties including p53 activity and SIFT-
class, for details, see Additional file 1: Methods 2.
Bisulfite conversion
For initial bisulfite conversion, 250 ng (MIR34A/B/C)
and 125 ng (DAPK) of DNA/sample were applied using
the EZ DNA Methylation Kit (Zymo Research) accord-
ing to the manufacturers’ recommendations.
Methylation-specific melting curve analysis of MIR34A/B/C
The methylation status of the MIR34A and MIR34 B/C
promoters was examined using methylation-specific
melting curve analysis (MS-MCA); The amplification
was carried out on a LightCycler® 480 instrument II
(Roche Diagnostics) [4, 18, 24, 49]. The DNA sequences
analyzed for promoter hypermethylation are located near
the transcription start sites and in the promoter CpG-
islands as previously described [4, 7, 24, 46]. The melting
peaks were calculated using the LightCycler® 480 Soft-
ware, Release 1.5.0SP3. Methylated DNA (Chemicon,
Millipore, Billerica, MA, USA), unmethylated DNA
(Qiagen), and a no template control (NTC) were in-
cluded in all experiments.
DAPK methylation analysis using allelic MSP-
pyrosequencing
The DAPK methylation specific PCR (MSP) primers tar-
get the antisense strand and amplify the region sur-
rounding the rs13300553 SNP (A/G), as described
previously [23, 24]. For primer sequences and detailed
methods see [22, 23], and Additional file 1: Methods 3.
Statistics
The statistical software used for the analyses was SPSS
version 22 for Windows (SPSS Inc. IBM, Armonk, NY,
USA) and R version 3.2.1 for Mac OS X, Leopard
(Apple, Cupertino, CA, USA). Analysis of categorical
data and their in between associations was done by
Fisher’s exact test, whereas t-test was used for continu-
ous data. Survival was calculated based on survival status
5 years (60 months) after date of diagnosis. Survival
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method, and the estimates were evaluated by the log-
rank test. The main outcomes were median overall
survival (OS) and progression free survival (PFS). Cox
proportional hazard method was applied to evaluate
which variables were independent prognostic factors.
The co-factors of the fitted models (sex, age, IPI) were
tested for proportionality using the Cox-Aalen test. The
significance level was defined as P-values < 0.05. All P-
values were two-sided.Ethics, consent and permissions
The project was conducted according to the Declaration
of Helsinki, and was approved by the regional ethics
committee (H-3-2012-127) and by the Danish data
protection committee (2007-58-0015) according to the
Danish ethical regulations.Results
Clinical and survival parameters in 107 PCNSL patients
TP53 mutation analysis was successful in 86/107 pa-
tients, and promoter methylation studies of the MIR34A,
MIR34B/C, and DAPK were successful in 93/107, 84/
107 and 75/107 patients, respectively. The clinicopatho-
logical data of the whole cohort (N = 107) and the TP53,
MIR34A, and DAPK subgroups are listed in Additional
file 2: Table S1a-d. These tables also include description
of the different treatment regimens and relevant doses
that patients received as 1st line therapy.
The median OS for the whole cohort was 9.2 months
[CI95%: 4.0–14.4], and the PFS was 6.7 months [CI95%:
3.7–9.6]. The mean and median follow-up time were
22.4 and 9.1 months (range: 0.1–157.5 months),
respectively.Fig. 1 Overall survival associated with 1st line treatment in 107 PCNSL pati
combination chemotherapy +/− rituximab, whole brain radiation therapy (Survival differed significantly according to 1st line
treatment modality. The 70 patients that received com-
bination chemotherapy with or without rituximab (CCT-
treated +/− rituximab) had a significantly longer median
OS of 31.3 months [CI 95 %: 12.6–44.3], as compared to
patients receiving monotherapy with high-dose metho-
trexate (HD-MTX), 6.0 months [CI 95 %: 1.6-NA],
whole brain radiation therapy (WBRT), 6.0 [CI 95 %:
2.1-NA], or no therapy, 0.83 months [CI 95 %: 0.57–2.2],
P < 0.0001, Fig. 1.
Disease status according to 1st line treatment is re-
corded in Additional file 2: Table S2a. At the end of
follow-up, 23 (21.5 %) patients were alive, and 20/23 in
partial- or complete remission; 84 (78.5 %) patients were
deceased. Twenty-two patients suffered a relapse after
1st line treatment (19 CCT +/− rituximab, and 3 HD-
MTX only), and received a second treatment, Additional
file 2: Table S2a-b. The median time to relapse after 1st
treatment in this group was 8.4 months (range: 1–60.8).
Among these patients, 2 (9.1 %) patients were in
complete remission and alive 51.5 and 52.0 months after
diagnosis, respectively, the remaining 20 (90.9 %) had
deceased. The two surviving patients were originally
treated with CCT + rituximab.
Histopathology and immunohistochemistry
HE-staining showed classical patterns of CNS DLBCL
with malignant angiocentric lymphocytic infiltration or
diffuse sheets of B-type lymphoma (CD20+, CD79+,
CD3-, CD5-) with immuno- or centroblast morphology,
Fig. 2a-d.
IHC marker expression of the whole cohort and the
three subgroups are shown in Additional file 2: Table S3
a-d. Briefly, the PCNSLs had an IHC-profile with the
majority expressing BCL2+ (62.3 %), BCL6+ (74.6 %),ents. Kaplan-Meier plot of 107 PCNSL patients, who were treated with
WBRT), high-dose (HD) methotrexate, and no therapy, P < 0.0001
Fig. 2 Histology and immunohistochemistry of PCNSL of the DLBCL-
subtype. PCNSL composed of large lymphocytic cells with irregular
immunoblastic and centroblastic nuclei, increased number of
mitoses, and (a) perivascular-, or (b) diffuse lymphoma infiltration.
Immunohistochemical (IHC) marker expression includes (c) CD20+
(B-cell staining) and (d) CD3- (B-cells not staining, reactive T-cells+).
IHC staining pattern of p53 protein in PCNSL tissue samples: (e) p53
++ (black arrow) in patient ID18 with a hotspot/direct DNA contact
MUT-TP53, p.R175H, (f) p53++ in patient ID14 with a hotspot/direct
DNA contact MUT-TP53, p.R248Q. (g) p53-, in a patient with WT-TP53,
and (h) p53+, in a patient with WT-TP53. Perivascular staining of p53
and neoplastic B-cells (black arrow)
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p53-IHC varied within specimens, and the number of
nuclei expressing p53 protein was highly variable, sug-
gesting tumor heterogeneity (Fig. 2e-h). In 86 % of the
specimens p53-IHC positivity was present.
Structural mutation profile of the TP53 gene in PCNSL
patients
Thirty-two of 86 (37.2 %) patients had one or more
TP53 mutations, resulting in 37 missense mutations, one
deletion, and one nonsense mutation. Thus, 7 (8 %) pa-
tients carried two mutations. Two SNVs occurred three
times each; p.R175H (hotspot) and p.M169I, and
p.T140I twice, leaving 34 different SNVs detected. The
classification of the absolute number of mutations isshown in detail in Table 1, which is divided in two; the
upper part (patient ID’s 1–24) representing patients that
received CCT-treatment, and the lower part (patient ID’s
25–32) representing patients that received other treat-
ment, but no CCT-therapy.
The structural analysis was restricted to the 24 CCT-
treated patients in concordance with the survival ana-
lyses described below. The distribution pattern of these
28 SNVs (4 patients had two TP53 mutations) was ana-
lyzed according to their position in the 3-dimensional
crystal model; 22/28 (78.6 %) were localized in codons
involved in DNA-binding motifs of the central core do-
main. These included 5 (17.9 %) in the Loop-L3 (codons
237–250) that interacts with the minor groove of the
DNA, and 5 (17.9 %) in the LSH-motif (codons 119–135
and 272–287) that interacts with the major groove of
the DNA, and 12 (42.9 %) in the Loop-L2 (codons 164–
194), which enhances the binding affinity between the
DNA-helix and TP53 under physiological conditions. In
9 (32.1 %) of the absolute numbers of mutations, the
mutated amino acid residues were involved in areas with
hotspot properties, direct DNA contact or the central
Zn-binding site, Table 1. All hotspot mutations were in-
tegrated in the direct DNA contact group. Location of
MUT-TP53 according to exons, highly conserved areas
and the distribution of basepair shifts are illustrated in
Additional file 3: Figure S1a-c. The missense mutations
could be classified according to their functionality, re-
vealing the capacity of transactivating the promoter
regions of several p53 target genes. Among the mis-
sense mutations, 14 (50.0 %) were predicted to inacti-
vate p53, 7 (25.0 %) were associated with partially
active p53, and 5 (17.9 %) with active p53. Among
the remaining 2 (7.1 %), a single base deletion was al-
located to the Zn-binding site. The SIFT-class predic-
tion model designated 22 (78.6 %) of the TP53
mutations as being deleterious, Table 1.Association between TP53 mutations, clinical
characteristics and survival
In the 86 patients with a successful TP53 mutational
analysis, complete or partial clinical data was available,
Additional file 2: Table S2b. There were no significant
differences in the clinical presentation patterns between
the 32 patients that carried one or more TP53 mutations
compared to the 54 patients with WT-TP53.
In these 86 patients, survival analysis did not reveal
any differences in OS between PCNSL cases with
MUT-TP53 versus WT-TP53 (Median OS: 13.1 vs.
9.1 months respectively, P = 0.625). At the end of fol-
low up, 27/32 (84.4 %) of the MUT-TP53 cases had
deceased as opposed to 41/54 (75.9 %) of the WT-
TP53 cases, and no differences in OS were seen
Table 1 Structural classification of TP53 mutations in primary central nervous system lymphoma. The structural classification includes an absolute number of 39 TP53 mutations
divided on 32 patients, of which 24 combination chemotherapy treated patients harbored 28 mutations (IDs 1–24), and the remaining 8, who harbored 11 mutations, received
other therapies (IDs 25–32)
ID Exon TP53
Mutation
Sequence
change
Protein
change
Basepair
change
Localization Hotspot
mutation
Direct DNA
contact/Zn
CpG Site Conserved
region
Siftclass Mutation
type
Transactivation
class
1 5I CYS-135-TYR TGC > TAC p.C135Y C.404G > A LSH 2 Deleterious Missense Non-Active
2 5I THR-140-ILE ACC > ATC p.T140I C.419C > T β 2 Deleterious Missense Partially Active
3 5I PRO-142-SER CCT > TCT p.P142S C.424C > T β 2 Deleterious Missense Partially Active
4a 5I GLN-144-STOP CAG > CTG p.Q144 C.430C > T β 99 Deleterious Nonsense NA
5a 5I ASP-148-ASN GAT > AAT p.D148N C.442G > A L2 3 Neutral Missense Active
6 5II MET-169-ILE ATG > ATA p.M169I C.507G > A L2 3 Partially Deleterious Missense Partially Active
7 5II MET-169-ILE ATG > ATA p.M169I C.507G > A L2 3 Partially Deleterious Missense Partially Active
8 5II MET-169-ILE ATG > ATA p.M169I C.507G > A L2 3 Partially Deleterious Missense Partially Active
9 5II GLU-171-LYS GAG > AAG p.E171K C.511G > A L2 3 Deleterious Missense Active
10a 5II VAL-173-MET GTG > ATG p.V173M C.517G > A L2 3 Deleterious Missense Non-Active
10b 5II ARG-181-HIS CGC > CAC p.R181H c.542G > A L2 CpG 3 Deleterious Missense Partially Active
11 5II ARG-175-HIS CGC > CAC p.R175H C.524G > A L2 Hotspot Direct DNA Contact CpG 3 Deleterious Missense Non-Active
12 5II ARG-175-HIS CGC > CAC p.R175H C.524G > A L2 Hotspot Direct DNA Contact CpG 3 Deleterious Missense Non-Active
5b 5II Frameshift deletion NA C.528.del1 L2 Zn-binding Site CpG 3 Frameshift Deletion NA (Zn-binding Site)
13 5II HIS-179-ARG CAT > CGT p.H179R C.536A > G L2 Hotspot Zn-binding Site 3 Deleterious Missense Non-Active
14 5II ASP-184-GLY GAT > GGT p.D184G C.551A > G L2 3 Neutral Missense Active
15 6 ARG-202-CYS CGT > TGT p.R202C C.604C > T β CpG 99 Deleterious Missense Active
16a 6 ASP-208-GLY GAC > GGC p.D208G C.623A > G β 99 Deleterious Missense Active
17 7 TYR-236-CYS TAC > TGC p.Y236C C.707A > G β 99 Deleterious Missense Non-Active
4b 7 MET-237-VAL ATG > GTG p.M237V C.709A > G L3 99 Deleterious Missense Non-Active
18 7 ASN-239-SER AAC > AGC p.N239S C.716A > G L3 Hotspot Direct DNA Contact 4 Deleterious Missense Non-Active
19 7 ARG-248-GLN CGG > CAG p.R248Q C.743G > A L3 Hotspot Direct DNA Contact CpG 4 Deleterious Missense Non-Active
20 7 ARG-249-LYS AGG > AAG p.R249K C.746G > A L3 Hotspot Direct DNA Contact 4 Deleterious Missense Non-Active
16b 7 THR-256-ILE ACA > ATA p.T256I C.767C > T L3 4 Deleterious Missense Partially Active
21 8 ARG-273-CYS CGT > TGT p.R273C C.817C > T LSH Hotspot Direct DNA Contact CpG 5 Deleterious Missense Non-Active
22 8 GLY-279-GLU GGG > GAG p.G279E C.836G > A LSH 5 Deleterious Missense Non-Active
23 8 ARG-280-LYS AGA > AAA p.R280K C.839G > A LSH Hotspot Direct DNA Contact 5 Deleterious Missense Non-Active
24 8 GLU-286-LYS GAA > AAA p.E286K C.856G > A LSH 5 Deleterious Missense Non-Active
25a 5I THR-140-ILE ACC > ATC p.T140I C.419C > T β 99 Deleterious Missense Partially Active
26a 5I PRO-151-SER CCC > CCT p.P151S C.451C > T β Direct DNA Contact 99 Deleterious Missense Non-Active
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Table 1 Structural classification of TP53 mutations in primary central nervous system lymphoma. The structural classification includes an absolute number of 39 TP53 mutations
divided on 32 patients, of which 24 combination chemotherapy treated patients harbored 28 mutations (IDs 1–24), and the remaining 8, who harbored 11 mutations, received
other therapies (IDs 25–32) (Continued)
27 5I ILE-162-MET ATC > ATG p.I162M C.486C > G β 99 Deleterious Missense Partially Active
28a 5II VAL-172-ALA GTG > GCG p.V172A C.515 T > C L2 3 Deleterious Missense Active
29 5II ARG-175-HIS CGC > CAC p.R175H C.524G > A L2 Hotspot Direct DNA Contact CpG 3 Deleterious Missense Non-Active
30 5II GLY-187-ASP GGT > GAT p.G187D C.560G > A L2 3 Neutral Missense Active
26b 5II GLY-187-ASP GGT > GAT p.G187D C.560G > A L2 3 Neutral Missense Active
31 7 MET-243-ILE ATG > ATA p.M243I C.729G > A L3 Direct DNA Contact 4 Deleterious Missense Non-Active
28b 8 VAL-272-MET GTG > ATG p.V272M C.814G > A LSH 5 Deleterious Missense Non-Active
32 8 ARG-290-CYS CGC > TGC p.R290C C.868C > T β CpG 99 Deleterious Missense Active
25b 8 GLY-302-ARG GGG > AGG p.G302R C.904G > A C-Term 99 Neutral Missense Active
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spectively (P = 0.46).
When the analyses were confined to the 57/86 (65.5 %)
CCT-treated patients, a potential biological difference be-
tween PCNSL harboringMUT-TP53 versusWT-TP53 was
observed, however, this was non-significant, Fig. 3a, b.
This observation prompted us to perform survival ana-
lyses based on the predicted structural subsets in the
group of CCT-treated PCNSL patients.
Prognostic impact of TP53 hotspot mutations/direct DNA
contact in CCT-treated patients
Because all hotspot mutations (n = 8) were an integrated
part of the direct DNA contact group (n = 9), we chose
to merge these groups into one. When the survival ana-
lyses were confined to the cohort of the 57 CCT-treated
PCNSL, the OS and PFS differed significantly for pa-
tients with hotspot/direct DNA contact- (n = 9) vs. non-
hotspot/non-direct DNA contact MUT-TP53 (n = 15) vs.
WT-TP53 (n = 32); in the OS analysis the median was
6.9 vs 33.7 vs 53.4 months, respectively, P = 0.041
whereas for the PFS, the median was 4.6 months vs. 18.2
vs 45.7 months, P = 0.00076, Fig. 3c, d. In an univariate-
and multivariate Cox regression model, presence of aFig. 3 Overall- and progression free survival of 57 PCNSL CCT-treated patie
(n = 24) showed a non-significant trend towards worse (a) OS, and (b) PFS
respectively. Presence of a TP53 hotspot/or direct DNA contact mutations (n
with non-hotspot/non-direct DNA contact TP53 mutations and WT-TP53, P =hotspot/direct DNA contact MUT-TP53 was highly pre-
dictive for poor outcome in both univariate- and multi-
variate analyses for both PFS P = 0.0046 (HR: 1.97,
[CI95%: 1.97–3.01]) and P = 0.0083 (HR: 1.95, [CI95%:
1.19–3.21]), respectively, and OS P = 0.028 (HR: 1.67,
[CI95%: 1.06–2.67]) and P = 0.012 (HR: 1.86, [CI95%:
1.14–3.01]), respectively, Table 2.
MUT-TP53 located to Loop-L2, Loop-L3, and LSH-
motifs, as well as mutations in the conserved regions 2–
5, or according to functional properties did not have any
association with survival outcomes (data not shown).
MIR34A and MIR34B/C methylation status and survival
outcome
Promoter methylation status of MIR34A and MIR34B/
C was successfully investigated in 93 and 84 patients.
The clinical data of patients with or without methyla-
tion of MIR34A are shown in Additional file 2:
Table S2c. Fifty-three of 93 (57.0 %) patients had pro-
moter methylation of MIR34A, and 80/84 (95.2 %) pa-
tients had promoter methylation of MIR34B/C. No
survival analysis was carried out for MIR34B/C, since
only 2 events occurred among the 4 patients desig-
nated as un-methylated.nts subjected to TP53 mutation analysis. Patients with MUT-TP53 (red)
compared to patients with WT-TP53 (blue), P = 0.16 and P = 0.10,
= 9) was indicative of poorer (c) OS, and (d) PFS compared to patients
0.041 and P = 0.00076, respectively
Table 2 Univariate- and multivariate Cox proportional hazard regression models of analyzed factors and clinical co-factors. Signifi-
cant P-values are written in italics
Survival outcome Univariate survival analysis Multivariate survival analysis
Factor Cox proportional hazard model Cox proportional hazard model
Co-factors P-value (Hazard ratio, [95 % confidence intervals]) P-value (Hazard ratio, [95 % confidence intervals])
Progression free survival
Hot Spot/Direct DNA Contact MUT-TP53 0.0046 (1.97, [1.14-3.01]) 0.0083 (1.95, [1.19–3.21])
Age 0.94 (1.0, [0.96–1.05])
Sex
Female 1.00 (1.00, [1.00–1.00])
Male 0.18 (0.63, [0.32–1.25])
IPI
Low 1.00 (1.00, [1.00–1.00])
High 0.36 (1.45, [0.65–3.24])
Overall survival
Hot Spot/Direct DNA Contact MUT-TP53 0.028 (1.67, [1.06–2.67]) 0.012 (1.86, [1.14–3.01])
Age 0.20 (1.03, [0.98–1.08])
Sex
Female 1.00 (1.00, [1.00–1.00])
Male 0.35 (0.71, [0.34–1.46])
IPI
Low 1.00 (1.00, [1.00–1.00])
High 0.42 (1.44, [0.59–3.48])
Progression free survival
Double Hit, MUT-TP53 and MIR34A-meth 0.010 (2.96, [1.29–6.76]) 0.066 (2.30, [0.95–5.57])
Age 0.73 (0.99, [0.95–1.04])
Sex
Female 1.00 (1.00, [1.00–1.00])
Male 0.07 (0.50, [0.24–1.06])
IPI
Low 1.00 (1.00, [1.00–1.00])
High 0.26 (1.69, [0.68–4.19])
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methylation of MIR34A alone was detected, neither in
the entire cohort, P = 0.63 and P = 0.84, respectively, nor
in the CCT-treated subcohort, P = 0.58 and P = 0.19, re-
spectively, Additional file 3: Figure S2a, b.
Impact of concomitant TP53 mutation and MIR34A
methylation on survival
Seventy-eight PCNSL cases, which had been analyzed
for both MUT-TP53 and MIR34A promoter methylation,
were matched pairwise to detect presence of “double
hit”. Eleven of 78 (14.1 %) had “double hit”. The
remaining 67/78 patients (85.9 %) that either had a TP53
mutation or a MIR34A promoter methylation, i.e. “single
hit”, or neither of them, were grouped together as “non-
double hit”. In the CCT-treated subcohort, 52/54 (96.3 %)of the patients entered the analysis, of whom 8/52
(15.4 %) had “double hit”. Presence of a “double hit” was
associated with a poorer PFS in the CCT-treated sub-
group, as compared to “non-double hit”. Eight of 8
(100 %) CCT-patients with “double hit” had all experi-
enced an event at follow-up (median PFS 6.4 months), in
comparison to 24/44 (54.5 %) in the “non-double hit” sub-
group, (median PFS 38.0 months), P = 0.0070, Fig. 4.
Noteworthy, among the CCT-treated patients 5/8 of
the “double hit” cases were hotspot/direct DNA contact
mutations (ID’s 5, 11, 20, 21, 23), and 3 non-hotspot/
non-direct DNA contact mutations (ID’s: 2, 7, 8). In the
Cox regression model, presence of a “double-hit” was
significant only in the univariate-, but not in the multi-
variate model, P = 0.010 (HR: 2.96, [CI95%: 1.29–6.76]
and P = 0.066 (HR: 2.30, [CI95%: 0.95–5.57]), Table 2.
Fig. 4 Concomitant TP53 mutation and MIR34A methylation “double-hit” associated with poorer progression free survival in CCT-treated PCNSL
patients. Kaplan-Meier plot of 52/57 PCNSL patients, of which the 8 patients with “double-hit” TP53 mutation and MIR34A promoter methylation
had a significantly poorer PFS. P = 0.0070
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Seventy-five of 107 (70.1 %) PCNSL FFPE samples were
successfully tested for DAPK promoter methylation and
70/75 (93.3 %) were methylated. The clinical data of pa-
tients with or without methylation of DAPK are presented
in Additional file 2: Table S2d. There was no significant
difference between OS/PFS of patients with or without
methylation of DAPK in the entire cohort, when analyzed
in CCT-treated patients only, or when combined with
MUT-TP53 data (data not shown). Data on the
rs13300553 SNP genotypes and allelic DAPK methylation
patterns are presented in Additional file 4: Data.Discussion
Here, we present data on a large cohort of 107 con-
secutively diagnosed PCNSL cases, with comprehensive
analyses of clinical data, histopathology, TP53 mutation
status, and MIR34A/B/C and DAPK promoter methyla-
tion. At the time of diagnosis 80 of 107 (75 %) cases
had disruption of one or more of the investigated
genes, indicating that disrupted p53-signaling may be
an essential part of PCNSL pathogenesis, which may
contribute to the aggressive phenotype.
We did not observe a general negative effect on out-
come by TP53 mutations in our entire cohort. How-
ever, when analyzing the subcohort of CCT-treated
PCNSL patients, Kaplan-Meier analysis showed an in-
verse relationship with both PFS and OS in cases with
MUT-TP53 in hotspots/direct DNA contact residues,
compared to cases with WT-TP53 or other types of
MUT-TP53. This observation was emphasized in multi-
variate Cox regression analyses, which showed that
presence of a hotspot/direct DNA contact mutation
was an independent negative prognostic factor for sur-
vival in CCT-treated PCNSL patients when adjusting
for sex, age and IPI-status.Previous studies have shown that TP53 mutation sta-
tus plays a pivotal role in predicting outcome in patients
with peripheral DLBCL treated with R-CHOP/CHOP-
like chemotherapy: Patients with MUT-TP53 have a 2-
fold higher relative risk of death compared to patients
with WT-TP53, and patients with TP53 mutations that
involved hotspot residues, and overlapping direct DNA
contact residues of the DBD had a high mortality rate
[51–53]. Our study of PCNSL consolidates the import-
ance of not only reporting the mere MUT-TP53 number,
but combines the structural classification in the survival
analyses, stressing the inverse association to outcome
when PCNSL patients harbor hotspot/direct DNA con-
tact MUT-TP53, as formerly shown in DLBCL and other
cancer subtypes [12, 26, 35, 42].
The reported frequency of somatic TP53 mutations in
lymphomas varies significantly [50], even within individ-
ual lymphoma subtypes across different studies, which is
likely due to differences in the quality of study material
and the applied methods [26]. TP53 mutation status in
PCNSL has only sporadically been reported in two other
cohorts revealing much lower incidences compared to
our study [10, 31]. In Cobbers’ pioneering work, 20
PCNSL patient samples (11 freshly frozen and 9 FFPE)
were subjected to single-strand conformation poly-
morphism analysis followed by gel electrophoresis and
DNA sequencing of TP53 exons 5–8, discovering only
one missense mutation at codon 248 in one of twenty
(5 %) patients [10]. In a recent work, 71 PCNSL patient
samples (48 freshly frozen and 23 FFPE) were screened
for mutations in 21 genes using the Ion Torrent NGS-
platform, revealing a TP53 mutation rate of 7 %. However,
validation by alternative methods was not performed for
TP53, and no detailed structural classification of MUT-
TP53 was provided in this study [31]. The primers of the
current commercial Ion Torrent NGS-platform would a
priori only cover 70.6 % of the detected TP53 mutations
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sess (e.g. homopolymeric tracts), and intra- and intertu-
mor heterogeneity may require additional depth and
coverage [28, 38].
When considering the reported low frequency of MUT-
TP53 in PCNSL, we speculated whether the observed high
frequency could be influenced by sequencing artifacts
resulting from the use of FFPE DNA [2], or if it repre-
sented a genuine high frequency of driving mutations with
clinical impact accompanied by random passenger muta-
tions of unknown relevance [8, 12, 41, 45]. The fact that
up to one mutation artifacts per 500 bases have been re-
ported in methodological analyses of FFPE tissue in DNA
sequencing with the majority of transitions being of C > T
or G > A type [48] could be an indication of the former
situation [12]. However, the previous studies mentioned
above also included a significant proportion of FFPE sam-
ples in their cohorts, and we have not observed notable
higher frequencies of TP53 mutations in FFPE compared
to fresh frozen samples in peripheral DLBCL using the
same methodology [22]. Finally, it could be argued that we
would not observe the clear inverse relationship between
hotspot/direct DNA contact TP53 mutations and clinical
survival parameters, confirmed by multivariate Cox regres-
sion analysis, if a significant proportion of the detected
mutations were randomly occurring artifacts. Thus, taken
together, our data suggest that the frequency of TP53 mu-
tations in PCNSL is higher than what has previously been
appreciated and consolidate the prognostic impact of hot-
spot/direct DNA contactMUT-TP53 in PCNSL.
Interestingly, we also observed higher frequencies of
MIR34A/B/C and DAPK promoter methylation than we
previously detected in DLBCL outside the CNS [4, 22]. As
in extra-CNS DLBCL we identified cases with concomi-
tantMUT-TP53 andMIR34A methylation to be associated
with a poor PFS. When combined with MIR34A methyla-
tion, also MUT-TP53 outside the hotspot/direct DNA
contact loci seem to influence outcome emphasizing the
synergistic function of these aberrations in lymphomagen-
esis. However, although we provide one of the largest mo-
lecular studies of PCNSL to date, the numbers of cases in
the individual groups are still small. Ideally, the prognostic
impact of hotspot/direct DNA contact TP53 mutations
and concomitant MUT-TP53 and MIR34A methylation
observed in this study, should be confirmed in other inde-
pendent cohorts. NGS is a preferred methodology in fu-
ture MUT-TP53 investigations, however, at least initially;
the observed mutational spectrum should be compared to
that obtained by other standard methods.
Conclusion
In conclusion, our data indicate that PCNSL have com-
prehensive molecular alterations in the p53-pathway,
and that the high disruption frequency of the p53-pathway contributes to the poor outcome in CCT-
treated PCNSL patients. In a clinical perspective, TP53
mutational and MIR34A methylation analyses of PCNSL
could serve as additional tools in the prognostic setting
when choosing treatment strategy. With referral to the
accumulating evidence that p53 hotspot mutants have
multiple gain of function properties [43], they may po-
tentially serve as therapeutic targets. Thus it is tempting
to speculate whether disruption of the p53-pathway may
identify patients that are candidates for emerging, alter-
native treatment options in PCNSL.
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